PT - JOURNAL ARTICLE AU - Shinichi Goto AU - Keitaro Mahara AU - Lauren Beussink-Nelson AU - Hidehiko Ikura AU - Yoshinori Katsumata AU - Jin Endo AU - Hanna K. Gaggin AU - Sanjiv J. Shah AU - Yuji Itabashi AU - Calum A MacRae AU - Rahul C Deo TI - Artificial Intelligence-Enabled, Fully Automated Detection of Cardiac Amyloidosis Using Electrocardiograms and Echocardiograms AID - 10.1101/2020.07.02.20141028 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.02.20141028 4099 - http://medrxiv.org/content/early/2020/07/05/2020.07.02.20141028.short 4100 - http://medrxiv.org/content/early/2020/07/05/2020.07.02.20141028.full AB - Although individually uncommon, rare diseases collectively affect over 350 million patients worldwide and are increasingly the target of therapeutic development efforts1. Unfortunately, the pursuit and use of such therapies have been hindered by a common challenge: patients with specific rare diseases are difficult to identify, especially if the conditions resemble more prevalent disorders. Cardiac amyloidosis is one such rare disease, which is characterized by deposition of misfolded proteins within the heart muscle resulting in heart failure and death2–4. In recent years, specific therapies have emerged for cardiac amyloidosis 5,6 and several more are under investigation7–9, but because cardiac amyloidosis is mistaken for common forms of heart failure, it is typically diagnosed late in its course. As a possible solution, artificial intelligence methods could enable automated detection of rare diseases, but model performance must address low disease prevalence. Here we present an automated multi-modality pipeline for cardiac amyloidosis detection using two neural-network models; one using electrocardiograms (ECG) and the second using echocardiographic videos as input. These models were trained and validated on 3 and 5 academic medical centers (AMC), respectively, in the United States and Japan. Both models had excellent accuracy for detecting cardiac amyloidosis with C-statistics of 0.85-0.92 and 0.91-1.00 for the ECG and echocardiography models, respectively, with the latter outperforming expert diagnosis. Simulating deployment on 13,906 and 7,775 patients with ECG-echocardiography paired data for AMC2 and AMC3 indicated a positive predictive value (PPV) for the ECG model of 4% and 3% at 61% and 54% recall, respectively. Pre-screening with ECG enhanced the echocardiography model performance from PPV 23% and 20% to PPV 58% and 53% at 64% recall, respectively for AMC2 and AMC3. In conclusion, we have developed a robust pipeline to augment detection of cardiac amyloidosis, which should serve as a generalizable strategy for other rare and intermediate frequency cardiac diseases with established or emerging therapies.Competing Interest StatementR.C.D is supported by grants from the National Institute of Health, the American Heart Association (One Brave Idea, Apple Heart and Movement Study) and GE Healthcare, has received consulting fees from Novartis and Pfizer, and is co-founder of Atman Health. S.J.S. is supported by grants from the National Institutes of Health (R01 HL140731, R01 HL120728, R01 HL107577, and R01 HL149423); the American Heart Association (#16SFRN28780016, #15CVGPSD27260148); Actelion, AstraZeneca, Corvia, and Novartis; and has received consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ionis, Ironwood, Merck, Novartis, Pfizer, Sanofi, and United Therapeutics. C.A.M. is a consultant for Pfizer and co-founder of Atman Health.Funding StatementThis work was supported by One Brave Idea, co-founded by the American Heart Association and Verily with significant support from AstraZeneca and pillar support from Quest Diagnostics (to CAM and RCD), NIH/NHLBI R01 HL140731 (to RCD), SENSHIN Medical Research Foundation (to SG), the Kanae foundation for the promotion of medical science (to SG), the Uehara Memorial Foundation and the Vehicle Racing Commemorative Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All the trial protocols and guidelines for the analyses were approved by the institutional review board at Partners Healthcare (protocol# 2019P002651).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code of the model is provided as supplementary material attached to this manuscript.